TLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TriSalus Life Sciences Inc (TLSI) is not a strong buy for a beginner, long-term investor at this time. While the company shows promising revenue growth and a high gross margin, its declining net income, EPS, and lack of strong trading signals or recent positive news make it less compelling. Additionally, analysts have lowered price targets, reflecting tempered expectations. The stock may be worth monitoring for future opportunities, but it does not present a strong case for immediate investment.
The MACD is positive and contracting, indicating mild bullish momentum. RSI is at 71.31, in the neutral zone, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support is at 4.167, and resistance is at 4.77. The stock is trading pre-market at 4.63, near its resistance level.
Revenue increased by 59.85% YoY in Q4 2025, and gross margin improved to 86.66%. Analysts maintain positive ratings despite lowering price targets.
Net income dropped by -10.45% YoY, and EPS declined significantly (-47.50%). Analysts have lowered price targets, reflecting tempered growth expectations. No recent news or significant trading trends from insiders or hedge funds.
In Q4 2025, revenue increased to $13.2M, up 59.85% YoY, indicating strong top-line growth. However, net income dropped to -$9.75M, and EPS fell to -0.21, showing worsening profitability. Gross margin improved slightly to 86.66%.
Analysts have lowered price targets recently: Northland reduced the target to $8 from $12.50, and Canaccord reduced it to $7 from $12. Both maintain positive ratings (Outperform and Buy, respectively), but expectations are tempered with a more sustainable growth trajectory.
